Cerebrospinal fluid analysis should be considered in patients with cognitive problems

International Journal of Alzheimer's Disease

Volumn , Issue , 2010, Pages

  Zetterberg, Henrik ^a   Mattsson, Niklas ^a   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUROFILAMENT PROTEIN; OLIGOCLONAL BAND; TAU PROTEIN;

ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EVALUATION; CREUTZFELDT JAKOB DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNOGLOBULIN PRODUCTION; LYME DISEASE; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NERVE FIBER DEGENERATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY; VERTEBRAL CANAL STENOSIS;

EID: 77956050470     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.4061/2010/163065     Document Type: Review

References (47)

1. Blennow K., de Leon M. J., Zetterberg H., Alzheimers disease The Lancet 2006 368 9533 387 403
2. Andreasen N., Minthon L., Davidsson P., Evaluation of CSF-tau and CSF-A 42 as diagnostic markers for Alzheimer disease in clinical practice Archives of Neurology 2001 58 3 373 379
3. Blennow K., Wallin A., Hager O., Low frequency of post-lumbar puncture headache in demented patients Acta Neurologica Scandinavica 1993 88 3 221 223
4. Peskind E. R., Riekse R., Quinn J. F., Safety and acceptability of the research lumbar puncture Alzheimer Disease and Associated Disorders 2005 19 4 220 225
5. Strozyk D., Blennow K., White L. R., Launer L. J., CSF A 42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 2003 60 4 652 656
6. Fagan A. M., Mintun M. A., Mach R. H., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta 42 in humans Annals of Neurology 2006 59 3 512 519
7. Forsberg A., Engler H., Almkvist O., PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiology of Aging 2008 29 10 1456 1465
8. Grimmer T., Riemenschneider M., Forstl H., Beta amyloid in Alzheimers disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid Biological Psychiatry 2009 65 11 927 934
9. Fagan A. M., Head D., Shah A. R., Decreased cerebrospinal fluid A 42 correlates with brain atrophy in cognitively normal elderly Annals of Neurology 2009 65 2 176 183
10. Gustafson D. R., Skoog I., Rosengren L., Zetterberg H., Blennow K., Cerebrospinal fluid -amyloid 1-42 concentration may predict cognitive decline in older women Journal of Neurology, Neurosurgery and Psychiatry 2007 78 5 461 464
11. Stomrud E., Hansson O., Blennow K., Minthon L., Londos E., Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly Dementia and Geriatric Cognitive Disorders 2007 24 2 118 124
12. Otto M., Esselmann H., Schulz-Schaeffer W., Decreased -amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neurology 2000 54 5 1099 1102
13. Trojanowski J. Q., Schuck T., Schmidt M. L., Lee V. M.-Y., Distribution of tau proteins in the normal human central and peripheral nervous system Journal of Histochemistry and Cytochemistry 1989 37 2 209 215
14. Lovestone S., Reynolds C. H., The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative process Neuroscience 1997 78 2 309 324
15. Mattsson N., Svman K., sterlundh G., Blennow K., Zetterberg H., Converging molecular pathways in human neural development and degeneration Neuroscience Research 2010 66 3 330 332
16. Ballatore C., Lee V. M.-Y., Trojanowski J. Q., Tau-mediated neurodegeneration in Alzheimers disease and related disorders Nature Reviews Neuroscience 2007 8 9 663 672
17. Hampel H., Blennow K., Shaw L. M., Hoessler Y. C., Zetterberg H., Trojanowski J. Q., Total and phosphorylated tau protein as biological markers of Alzheimers disease Experimental Gerontology 2010 45 1 30 40
18. Buerger K., Teipel S. J., Zinkowski R., CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects Neurology 2002 59 4 627 629
19. Buerger K., Ewers M., Pirttil T., CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimers disease Brain 2006 129 11 3035 3041
20. Bian H., Van Swieten J. C., Leight S., CSF biomarkers in frontotemporal lobar degeneration with known pathology Neurology 2008 70 19 1827 1835
21. Grossman M., Farmer J., Leight S., Cerebrospinal fluid profile in frontotemporal dementia and Alzheimers disease Annals of Neurology 2005 57 5 721 729
22. Blennow K., Johansson A., Zetterberg H., Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease International Journal of Molecular Medicine 2005 16 6 1147 1149
23. Riemenschneider M., Wagenpfeil S., Vanderstichele H., Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias Molecular Psychiatry 2003 8 3 343 347
24. Otto M., Wiltfang J., Cepek L., Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease Neurology 2002 58 2 192 197
25. Otto M., Wiltfang J., Tumani H., Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neuroscience Letters 1997 225 3 210 212
26. Hesse C., Rosengren L., Andreasen N., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke Neuroscience Letters 2001 297 3 187 190
27. Ost M., Nylen K., Csajbok L., Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury Neurology 2006 67 9 1600 1604
28. Zetterberg H., Hietala M. A., Jonsson M., Neurochemical aftermath of amateur boxing Archives of Neurology 2006 63 9 1277 1280
29. Samgard K., Zetterberg H., Blennow K., Hansson O., Minthon L., Londos E., Cerebrospinal fluid total tau as a marker of Alzheimers disease intensity International Journal of Geriatric Psychiatry 2009 25 4 403 410
30. Blom E. S., Giedraitis V., Zetterberg H., Rapid progression from mild cognitive impairment to Alzheimers disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype Dementia and Geriatric Cognitive Disorders 2009 27 5 458 464
31. Buerger K., Ewers M., Andreasen N., Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study Neurology 2005 65 9 1502 1503
32. Bostrom F., Hansson O., Blennow K., Cerebrospinal fluid total tau is associated with shorter survival in dementia with lewy bodies Dementia and Geriatric Cognitive Disorders 2009 28 4 314 319
33. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L., Association between CSF biomarkers and incipient Alzheimers disease in patients with mild cognitive impairment: a follow-up study Lancet Neurology 2006 5 3 228 234
34. Mattsson N., Zetterberg H., Hansson O., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment Journal of the American Medical Association 2009 302 4 385 393
35. Shaw L. M., Vanderstichele H., Knapik-Czajka M., Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects Annals of Neurology 2009 65 4 403 413
36. Visser P. J., Verhey F., Knol D. L., Prevalence and prognostic value of CSF markers of Alzheimers disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study The Lancet Neurology 2009 8 7 619 627
37. Rosengren L. E., Karlsson J.-E., Sjogren M., Blennow K., Wallin A., Neurofilament protein levels in CSF are increased in dementia Neurology 1999 52 5 1090 1093
38. Agren-Wilsson A., Lekman A., Sjoberg W., CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus Acta Neurologica Scandinavica 2007 116 5 333 339
39. Wallin A., Sjogren M., Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia Mechanisms of Ageing and Development 2001 122 16 1937 1949
40. de Jong D., Jansen R. W., Pijnenburg Y. A. L., CSF neurofilament proteins in the differential diagnosis of dementia Journal of Neurology, Neurosurgery and Psychiatry 2007 78 9 936 938
41. Norgren N., Sundstrm P., Svenningsson A., Rosengren L., Stigbrand T., Gunnarsson M., Neurofilament and glial fibrillary acidic protein in multiple sclerosis Neurology 2004 63 9 1586 1590
42. Gisslen M., Hagberg L., Brew B. J., Cinque P., Price R. W., Rosengren L., Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex Journal of Infectious Diseases 2007 195 12 1774 1778
43. Reiber H., Peter J. B., Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs Journal of the Neurological Sciences 2001 184 2 101 122
44. Blennow K., Wallin A., Fredman P., Karlsson I., Gottfries C. G., Svennerholm L., Blood-brain barrier disturbance in patients with Alzheimers disease is related to vascular factors Acta Neurologica Scandinavica 1990 81 4 323 326
45. Wallin A., Blennow K., Rosengren L., Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype Alzheimer Disease and Associated Disorders 1999 13 3 S102 S105
46. Tumani H., Nolker G., Reiber H., Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis Neurology 1995 45 9 1663 1670
47. Blennow K., Wallin A., Fredman P., Gottfries C. G., Karlsson I., Svennerholm L., Intrathecal synthesis of immunoglobulins in patients with Alzheimers disease European Neuropsychopharmacology 1990 1 1 79 81